Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model

Justin G. Julander, Dennis W. Trent, Thomas P. Monath

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. We recently reported development of a potentially safer β-propiolactone-inactivated whole virion YF vaccine (XRX-001), which was highly immunogenic in mice, hamsters, monkeys, and humans [10,11]. To characterize the protective efficacy of neutralizing antibodies stimulated by the inactivated vaccine, graded doses of serum from hamsters immunized with inactivated XRX-001 or live 17D vaccine were transferred to hamsters by the intraperitoneal (IP) route 24h prior to virulent, viscerotropic YF virus challenge. Neutralizing antibody (PRNT 50) titers were determined in the sera of treated animals 4h before challenge and 4 and 21 days after challenge. Neutralizing antibodies were shown to mediate protection. Animals having 50% plaque reduction neutralization test (PRNT 50) titers of ≥40 4h before challenge were completely protected from disease as evidenced by viremia, liver enzyme elevation, and protection against illness (weight change) and death. Passive titers of 10-20 were partially protective. Immunization with the XRX-001 vaccine stimulated YF neutralizing antibodies that were equally effective (based on dose response) as antibodies stimulated by live 17D vaccine. The results will be useful in defining the level of seroprotection in clinical studies of new yellow fever vaccines.

Original languageEnglish (US)
Pages (from-to)6008-6016
Number of pages9
JournalVaccine
Volume29
Issue number35
DOIs
StatePublished - Aug 11 2011

Fingerprint

Yellow Fever Vaccine
Yellow fever virus
Yellow Fever
Passive Immunization
Neutralizing Antibodies
hamsters
Cricetinae
immunization
neutralizing antibodies
vaccines
live vaccines
Vaccines
Propiolactone
Neutralization Tests
Attenuated Vaccines
Inactivated Vaccines
Viremia
Serum
Virion
inactivated vaccines

Keywords

  • 17D
  • Hamster
  • Immune correlates
  • Inactivated vaccine
  • Neutralizing antibodies
  • Passive immunization
  • Yellow fever

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. / Julander, Justin G.; Trent, Dennis W.; Monath, Thomas P.

In: Vaccine, Vol. 29, No. 35, 11.08.2011, p. 6008-6016.

Research output: Contribution to journalArticle

Julander, Justin G. ; Trent, Dennis W. ; Monath, Thomas P. / Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. In: Vaccine. 2011 ; Vol. 29, No. 35. pp. 6008-6016.
@article{852c1c1271ae4e0c84e7f057fb3179ed,
title = "Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model",
abstract = "Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. We recently reported development of a potentially safer β-propiolactone-inactivated whole virion YF vaccine (XRX-001), which was highly immunogenic in mice, hamsters, monkeys, and humans [10,11]. To characterize the protective efficacy of neutralizing antibodies stimulated by the inactivated vaccine, graded doses of serum from hamsters immunized with inactivated XRX-001 or live 17D vaccine were transferred to hamsters by the intraperitoneal (IP) route 24h prior to virulent, viscerotropic YF virus challenge. Neutralizing antibody (PRNT 50) titers were determined in the sera of treated animals 4h before challenge and 4 and 21 days after challenge. Neutralizing antibodies were shown to mediate protection. Animals having 50{\%} plaque reduction neutralization test (PRNT 50) titers of ≥40 4h before challenge were completely protected from disease as evidenced by viremia, liver enzyme elevation, and protection against illness (weight change) and death. Passive titers of 10-20 were partially protective. Immunization with the XRX-001 vaccine stimulated YF neutralizing antibodies that were equally effective (based on dose response) as antibodies stimulated by live 17D vaccine. The results will be useful in defining the level of seroprotection in clinical studies of new yellow fever vaccines.",
keywords = "17D, Hamster, Immune correlates, Inactivated vaccine, Neutralizing antibodies, Passive immunization, Yellow fever",
author = "Julander, {Justin G.} and Trent, {Dennis W.} and Monath, {Thomas P.}",
year = "2011",
month = "8",
day = "11",
doi = "10.1016/j.vaccine.2011.06.034",
language = "English (US)",
volume = "29",
pages = "6008--6016",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "35",

}

TY - JOUR

T1 - Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model

AU - Julander, Justin G.

AU - Trent, Dennis W.

AU - Monath, Thomas P.

PY - 2011/8/11

Y1 - 2011/8/11

N2 - Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. We recently reported development of a potentially safer β-propiolactone-inactivated whole virion YF vaccine (XRX-001), which was highly immunogenic in mice, hamsters, monkeys, and humans [10,11]. To characterize the protective efficacy of neutralizing antibodies stimulated by the inactivated vaccine, graded doses of serum from hamsters immunized with inactivated XRX-001 or live 17D vaccine were transferred to hamsters by the intraperitoneal (IP) route 24h prior to virulent, viscerotropic YF virus challenge. Neutralizing antibody (PRNT 50) titers were determined in the sera of treated animals 4h before challenge and 4 and 21 days after challenge. Neutralizing antibodies were shown to mediate protection. Animals having 50% plaque reduction neutralization test (PRNT 50) titers of ≥40 4h before challenge were completely protected from disease as evidenced by viremia, liver enzyme elevation, and protection against illness (weight change) and death. Passive titers of 10-20 were partially protective. Immunization with the XRX-001 vaccine stimulated YF neutralizing antibodies that were equally effective (based on dose response) as antibodies stimulated by live 17D vaccine. The results will be useful in defining the level of seroprotection in clinical studies of new yellow fever vaccines.

AB - Live, attenuated yellow fever (YF) 17D vaccine is highly efficacious but causes rare, serious adverse events resulting from active replication in the host and direct viral injury to vital organs. We recently reported development of a potentially safer β-propiolactone-inactivated whole virion YF vaccine (XRX-001), which was highly immunogenic in mice, hamsters, monkeys, and humans [10,11]. To characterize the protective efficacy of neutralizing antibodies stimulated by the inactivated vaccine, graded doses of serum from hamsters immunized with inactivated XRX-001 or live 17D vaccine were transferred to hamsters by the intraperitoneal (IP) route 24h prior to virulent, viscerotropic YF virus challenge. Neutralizing antibody (PRNT 50) titers were determined in the sera of treated animals 4h before challenge and 4 and 21 days after challenge. Neutralizing antibodies were shown to mediate protection. Animals having 50% plaque reduction neutralization test (PRNT 50) titers of ≥40 4h before challenge were completely protected from disease as evidenced by viremia, liver enzyme elevation, and protection against illness (weight change) and death. Passive titers of 10-20 were partially protective. Immunization with the XRX-001 vaccine stimulated YF neutralizing antibodies that were equally effective (based on dose response) as antibodies stimulated by live 17D vaccine. The results will be useful in defining the level of seroprotection in clinical studies of new yellow fever vaccines.

KW - 17D

KW - Hamster

KW - Immune correlates

KW - Inactivated vaccine

KW - Neutralizing antibodies

KW - Passive immunization

KW - Yellow fever

UR - http://www.scopus.com/inward/record.url?scp=79960710146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960710146&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.06.034

DO - 10.1016/j.vaccine.2011.06.034

M3 - Article

VL - 29

SP - 6008

EP - 6016

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 35

ER -